Compare MD & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | VCEL |
|---|---|---|
| Founded | 1979 | 1989 |
| Country | United States | United States |
| Employees | 4485 | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1995 | 1997 |
| Metric | MD | VCEL |
|---|---|---|
| Price | $21.81 | $37.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.00 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 681.9K | 586.8K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | ★ 1.91 | 0.25 |
| Revenue | ★ $1,922,442,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | $2.70 | $18.55 |
| P/E Ratio | ★ $11.45 | $151.65 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $11.84 | $29.24 |
| 52 Week High | $24.99 | $63.00 |
| Indicator | MD | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 48.73 |
| Support Level | $21.67 | $35.99 |
| Resistance Level | $22.78 | $41.65 |
| Average True Range (ATR) | 0.64 | 1.75 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 45.16 | 32.12 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.